Search
ALKS 27
go.drugbank.com/drugs/DB05752ExperimentalALKS 27 is an inhaled formulation of trospium chloride for the treatment of chronic obstructive pulmonary disease (COPD).
Zunsemetinib
go.drugbank.com/drugs/DB16502InvestigationalAdditionally, ATI-450 was studied in a terminated trial (NCT05511519) to treat patients with psoriatic arthritis. … Zunsemetinib is being investigated in a new clinical trial (NCT06374459) for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with bone metastasis.
rhMBL
go.drugbank.com/drugs/DB05237InvestigationalrhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL). … Over 10 percent of the general population is estimated to be MBL-deficient. Natural MBL is a 400-700kDa oligomer made of 3 identical 32kDa peptide chains.
Cannabinor
go.drugbank.com/drugs/DB05048ExperimentalCannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.
CY301
go.drugbank.com/drugs/DB06382ExperimentalCY301 (Simplivir) is an investigational gene silencing compound developed by CytoGenix for the treatment of HSV.
ETC-588
go.drugbank.com/drugs/DB05456Experimentaland other lipids from cells including those in the arterial wall. … It is believed that the removal of cholesterol by ETC-588 through this pathway may result in the reversal of atherosclerosis.
Dicloxacillin
go.drugbank.com/drugs/DB00485ApprovedInvestigationalVet approvedOne of the penicillins which is resistant to penicillinase.
Sobuzoxane
go.drugbank.com/drugs/DB21119ExperimentalSobuzoxane is a small molecule drug. The usage of the INN stem '-oxan(e)' in the name indicates that Sobuzoxane is a benzodioxane derivative.
Categories: Topoisomerase II InhibitorsProgabide
go.drugbank.com/drugs/DB00837ExperimentalProgabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. … In clinical trials, progabide has been investigated for Parkinson's disease, schizophrenia, clinical depression and anxiety disorder; its therapeutic effectiveness in these conditions is not fully elucidated